Takeda Launches First-in-Class Narcolepsy Drug

Takeda’s Orzeyful is now available in the U.S. by prescription for the treatment of narcolepsy type 1 in adults, bringing the first and only orexin agonist to this patient population.

The FDA approved the oral OX2R agonist in August, pending controlled substance classification. Orzeyful has since been classified as a schedule IV controlled substance (CIV), a category of drugs defined by the DEA as having low potential for abuse and low risk of physical or psychological dependence.

By stimulating OX2R, Orzeyful treats orexin deficiency, therefore increasing wakefulness and reducing abnormal REM phenomena. This provides a holistic therapy rather than treating individual symptoms. In clinical trials, the medication led to improvements in symptoms including excessive daytime sleepiness, cataplexy, and health-related quality of life.

 

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers from Tablets & Capsules – all delivered right to your inbox! Sign up now!